Cover Image
市場調查報告書

AVEO Pharmaceuticals, Inc.:開發中產品分析

AVEO Pharmaceuticals, Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 204904
出版日期 內容資訊 英文 62 Pages
訂單完成後即時交付
價格
Back to Top
AVEO Pharmaceuticals, Inc.:開發中產品分析 AVEO Pharmaceuticals, Inc. - Product Pipeline Review - 2016
出版日期: 2016年05月31日 內容資訊: 英文 62 Pages
簡介

AVEO Pharmaceuticals, Inc.是專門針對各種抗癌劑的開發實驗及銷售的企業。該公司的主要產品有Tivozanib(蛋白酪氨酸激梅抑制劑)、Ficlatuzumba(肝細胞成長因素的阻礙抗體)、AV-203(抗ErbB3單株抗體)、AV-380(人體化IgG1阻礙單株抗體)等。AVEO獨自開發的Human Response Platform便是以新種類臨床實驗前癌症模式,以拓寬傳統型異質體移植片模式的諸多限制而設計的。

本報告提供美國的生物醫藥品企業──AVEO Pharmaceuticals, Inc.(AVEO Oncology)的醫藥品研究開發進展相關分析,提供該公司的產品平台結構,及臨床實驗的整體進展,主要開發中產品的簡介與開發情形,以及該公司簡介及最新趨勢等調查。

目錄

AVEO Pharmaceuticals, Inc.:現狀

  • 企業概要
  • 主要資訊
  • 主要資料

研究開發(R&D)概況

  • 主要的治療領域

開發平台·檢討

  • 各開發階段的開發中產品
  • 開發中產品:單劑治療藥
  • 開發中產品:合作夥伴產品
    • 合作夥伴產品/並用治療模式
  • 開發中產品:合作產品
    • 合作產品/並用治療模式

開發中產品的概要

  • 後期階段的開發中產品
    • 未獲准登記產品/並用治療模式
  • 臨床實驗階段的開發中產品
    • PhaseⅡ產品/並用治療模式
    • PhaseⅠ產品/並用治療模式
  • 初期階段的開發中產品
    • 臨床實驗前產品/並用治療模式
    • 藥物研發階段的產品/並用治療模式

藥物簡介

  • tivozanib
    • 產品概要
    • 作用機制
    • 研究開發(R&D)的發展
  • ficlatuzumab
  • AV-203
  • AV-232
  • GP-369
  • Anti-Notch2單株抗體
  • Anti-Notch3單株抗體
  • Anti-Notch4單株抗體
  • AV-380
  • FGFR1阻礙單株抗體
  • FGFR4阻礙單株抗體

開發平台分析

  • 標的別
  • 各投藥法
  • 分子類別
  • 各作用機制

開發中產品的最新趨勢

暫停開發的產品

中止開發的產品

  • 中止開發的產品簡介
    • AV-412
    • tivozanib

企業的聲明

公司所在地及子公司

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08059CDB

Summary

Global Markets Direct's, 'AVEO Pharmaceuticals, Inc. - Product Pipeline Review - 2016', provides an overview of the AVEO Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by AVEO Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of AVEO Pharmaceuticals, Inc.
  • The report provides overview of AVEO Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses AVEO Pharmaceuticals, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features AVEO Pharmaceuticals, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate AVEO Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for AVEO Pharmaceuticals, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding AVEO Pharmaceuticals, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • AVEO Pharmaceuticals, Inc. Snapshot
    • AVEO Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • AVEO Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • AVEO Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • AVEO Pharmaceuticals, Inc. - Pipeline Products Glance
    • AVEO Pharmaceuticals, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • AVEO Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • AVEO Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • AVEO Pharmaceuticals, Inc. - Drug Profiles
    • tivozanib hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ficlatuzumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AV-203
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AV-232
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AV-353
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GP-369
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AV-370
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize FGFR1 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize FGFR4 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Target Notch2 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Target Notch3 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Target Notch4 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • AVEO Pharmaceuticals, Inc. - Pipeline Analysis
    • AVEO Pharmaceuticals, Inc. - Pipeline Products by Target
    • AVEO Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • AVEO Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • AVEO Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • AVEO Pharmaceuticals, Inc. - Recent Pipeline Updates
  • AVEO Pharmaceuticals, Inc. - Dormant Projects
  • AVEO Pharmaceuticals, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • AV-412
      • tivozanib hydrochloride
  • AVEO Pharmaceuticals, Inc. - Company Statement
  • AVEO Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • AVEO Pharmaceuticals, Inc., Key Information
  • AVEO Pharmaceuticals, Inc., Key Facts
  • AVEO Pharmaceuticals, Inc. - Pipeline by Indication, 2016
  • AVEO Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • AVEO Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • AVEO Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016
  • AVEO Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2016
  • AVEO Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2016
  • AVEO Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • AVEO Pharmaceuticals, Inc. - Phase III, 2016
  • AVEO Pharmaceuticals, Inc. - Phase II, 2016
  • AVEO Pharmaceuticals, Inc. - Phase I, 2016
  • AVEO Pharmaceuticals, Inc. - Preclinical, 2016
  • AVEO Pharmaceuticals, Inc. - Discovery, 2016
  • AVEO Pharmaceuticals, Inc. - Pipeline by Target, 2016
  • AVEO Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
  • AVEO Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • AVEO Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016
  • AVEO Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016
  • AVEO Pharmaceuticals, Inc. - Dormant Developmental Projects,2016
  • AVEO Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2016
  • AVEO Pharmaceuticals, Inc., Subsidiaries

List of Figures

  • AVEO Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016
  • AVEO Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • AVEO Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • AVEO Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016
  • AVEO Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2016
  • AVEO Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
  • AVEO Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • AVEO Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top